Brief: Mindset Pharma Receives Scientific Advice From UK Regulator Facilitating Advancement Of Phase 1 First-In-Human Clinical Trial Plan
14/09/2022 14:11
Sept 14 (Reuters) - Mindset Pharma Inc MSET.CD :
* MINDSET PHARMA RECEIVES SCIENTIFIC ADVICE FROM UK
REGULATOR
FACILITATING ADVANCEMENT OF PHASE 1 FIRST-IN-HUMAN CLINICAL
TRIAL PLAN FOR ITS LEAD CLINICAL CANDIDATE, MSP-1014
Source text for Eikon: ID:nGNX9TqJ9X
Further company coverage: MSET.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mindset pharma
See all newsStifel GMP sees significant uncertainty for Reunion Neuroscience over lawsuit
Brief: Reunion Neuroscience Files Lawsuit Against Mindset Pharma
Brief: Mindset Pharma announced Exclusive Licensing Agreement For Cybin To Acquire Intellectual Property Rights For Subset Of Co's Preclinical Compounds
Brief: Mindset Pharma Receives Scientific Advice From UK Regulator Facilitating Advancement Of Phase 1 First-In-Human Clinical Trial Plan
Brief: Mindset Pharma Enters Manufacturing Agreement With Leading CDMO To Produce Pharmaceutical Grade Batches Of Next-Generation Psilocybin Drug Candidate, Msp-1014